Please login to the form below

Not currently logged in
Email:
Password:

Alapis opens veterinary companies in Serbia and Hungary

Alapis establishes two companies in Serbia and Hungary which will specialise in the production and trade of veterinary medicines and foods

Greek pharmaceutical and chemical company Alapis has established two companies, one in Serbia and another in Hungary, both of which will specialise in the production and trade of veterinary medicines and foods.

The Serbia-based operation is called Veterin Pharma Doo and has its headquarters in Beograd. The other company, based in Budapest, Hungary, is called Veterin Hungary. Alapis is the sole share holder in both companies.

Other purchasing activity
On 25 July, Alapis said that it had been selected as the highest bidder by the Serbian Privatisation Agency for the sale of a 68.3 per cent stake in pharmaceutical distribution company Sumadijalek after it bid EUR 2.2m.

Sumadijalek was founded in 1965 and had turnover of EUR 9.4m in FY05 with 48 per cent of its sales coming from pharmacies, clinics and public hospitals.

Alapis reported that negotiations would begin with the agency for the purpose of signing the contract of purchase.

In early July, Alapis revealed that it was in preliminary talks with Bayer Cropscience's local unit Bayer Hellas to acquire its pesticide plant in Viotia, Greece. As part of the transaction, Alapis said it expected to take over the production of crop chemicals in the region for Bayer.

Alapis already co-operates with Germany-headquartered Bayer on the production of veterinary drugs in Greece, Romania and Bulgaria.

1st August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics